Of all the cases of economic espionage charged by the DOJ's National Security Division since 2012, more than 80% of them implicated China.World Politicsread more
"Whilst there is a big dispute at the moment, I think there's also potential for resolution," UBS chairman Axel Weber says of the U.S.-China trade negotiations.Singapore Summitread more
Cryptocurrency fans will hope the futures contracts, which are federally regulated, can provide some much-needed legitimacy to bitcoin.Cryptocurrencyread more
Despite mixed fan and critic reactions to the final season of "Game of Thrones," the eight-season epic took home the top prize in the drama category at the Emmy Awards on...Entertainmentread more
There are alternative financial centers and investors can turn to Singapore, Tokyo or Shanghai if Hong Kong doesn't "shape up," says the founder and chairman of Citic Capital.Singapore Summitread more
The Kingdom and oil and gas industry have been slow to shore up defenses, raising red flags about the possibility of longer term fall-out in the region.Technologyread more
Tensions between South Korea and Japan may ultimately disrupt the high-end tech sectors, says Heenam Choi, CEO at South Korea's sovereign wealth fund.Singapore Summitread more
On Sunday, the 71st Primetime Emmy Awards honored the best comedies, dramas, limited and variety series from the last year.Entertainmentread more
U.S. President Donald Trump's national security advisor said on Sunday that White House Asia policy adviser Matt Pottinger would become his top deputy.Politicsread more
Removing Neumann is a difficult decision for Son, who has long believed in WeWork and Neumann's vision to quickly expand the company.Technologyread more
Datadog went public on Thursday and instantly hit a $10 billion valuation, becoming the fourth cloud software debut to reach that level this year.Technologyread more
Researchers say they're one step closer to finding a potential cure for HIV after successfully eliminating the virus in living mice for the first time.
Using a combination of CRISPR gene-editing technology and a therapeutic treatment called LASER ART, scientists at Temple University and the University of Nebraska Medical Center said they erased HIV DNA from the genomes of animals in what they call an unprecedented study that was published Tuesday in the journal Nature Communications.
"We think this study is a major breakthrough because it for the first time demonstrates after 40 years of the AIDS epidemic that the HIV disease is a curable disease," said study co-author Dr. Kamel Khalili, chair of the department of neuroscience and director of the Center for Neurovirology and the Comprehensive NeuroAIDS Center at Temple University.
About 1.1 million people in the U.S. live with HIV, a virus that attacks the body's immune system and makes a person more susceptible to falling ill. If HIV is not treated, it can turn into AIDS, the late stage of HIV in which the virus badly damages the immune system. People with AIDS on average live about three years after their diagnosis, according to HIV.gov.
The virus is currently treated with antiretroviral therapy (ART), which suppresses it from replicating and prevents many patients in the U.S. from developing AIDS. ART does not rid the body of HIV, though, and if a patient stops treatment the virus will continue to replicate.
But now researchers say they're able to destroy the virus in "humanized" mice, which were injected with human bone marrow to imitate the human immune system.
The study authors used two different tools to combat the virus: CRISPR technology and LASER ART.
CRISPR-Cas9 is a gene editing tool that's been boasted as breakthrough technology that can help researchers treat or potentially cure genetic diseases. It gives scientists the ability to change an organism's DNA, so they can add, remove or change certain genetic material.
LASER ART is a "super" form of ART that keeps replication of the virus at low levels for longer time periods, according to co-author Dr. Howard Gendelman, chair of UNMC's pharmacology and experimental neuroscience department and director of the the Center for Neurodegenerative Diseases. The antiretroviral drug is then stored in nanocrystals, which slowly release the drug where the virus is located.
"We're going at the root cause," Gendelman said. "We're going after the virus that's already integrated in the genome of the host cell."
The researchers said they used the two treatments concurrently. First, they administered the LASER ART to reduce HIV growth, then they used the CRISPR treatment as "chemical scissors" to "eliminate the residual integrated HIV DNA still present," Gendelman said.
The virus did not return in nine of the 21 mice in which the method was tested, according to Khalili.
The study authors say the findings are promising and they are now testing the CRISPR-LASER ART combination on primates. However, there is still much work that needs to be done before the method can be tested on humans.
"Things that work in mice, may not work in men," Gendelman said. "The limitations of any mouse work have to do with the species, how the drug is administered, the distribution, which is a lot easier than a man or a woman."
Gendelman noted humans are much larger than mice, so there are a lot more HIV DNA scientists will have to destroy if they test in humans. Khalili also said steps still need to be taken to increase efficiency and safety of the method, but the data from this study has researchers "hopeful" it will work in primates and that they are "cautious, but very aggressive" moving forward with testing.
The researchers aim to be granted approval by the Food and Drug Administration to conduct a phase 1 clinical trial in humans by mid-2020, Khalili said.
Though the study was conducted on mice, Gendelman said it's still important because it shows that sterilization of HIV in living animals is possible.
"We are at the cusp of a scientific revolution in human genomes that can change the course, quality and longevity of life," Gendelman said.
Clarification: This article was updated to describe AIDS as the late stage of HIV.